Trials / Completed
CompletedNCT04577885
A Rifampin Effect Study of SHR2554 on Healthy Chinese Adult Subjects
A Single-center, Open, Single Does, Drug-drug Interaction Study to Investigate the Effects of Rifampin on the Pharmacokinetics of Healthy Chinese Adult Subjects After Oral Administration of SHR2554 Tablets
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of the study is to evaluate the effect of Rifampin on pharmacokinetics of healthy Chinese adult subjects after oral administration of SHR2554 tablets. The secondary objective of the study is to evaluate the safety of single-dose oral administration of SHR2554 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR2554 and Rifampin | Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules |
Timeline
- Start date
- 2020-05-28
- Primary completion
- 2020-08-30
- Completion
- 2020-09-20
- First posted
- 2020-10-08
- Last updated
- 2020-10-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04577885. Inclusion in this directory is not an endorsement.